{"id":"W4400998846","doi":"10.1186/s12885-023-11316-0","title":"Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study","year":2024,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Tryptophan and brain disorders","field":"Neuroscience","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Jewish General Hospital; Hôtel-Dieu de Québec","funders":"Merck Sharp and Dohme; Astellas Pharma; Eisai; Incyte; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Pembrolizumab; Medicine; Tolerability; Head and neck squamous-cell carcinoma; Oncology; Clinical endpoint; Internal medicine; Regimen; Phases of clinical research; Clinical trial; Ipilimumab; Adverse effect; Head and neck cancer; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002764896,0.0003965485,0.0006972377,0.0002271123,0.0001393492,0.0003856033,0.000426912,0.0000523619,0.0001375477],"category_scores_gemma":[0.0002239641,0.0003027886,0.00005887487,0.0007876587,0.0002140616,0.0004783172,0.0002312331,0.0003527387,0.00003335745],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002149692,"about_ca_system_score_gemma":0.0004564108,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001094607,"about_ca_topic_score_gemma":0.002070354,"domain_scores_codex":[0.9969742,0.0004731071,0.0004758053,0.001025521,0.0004984394,0.0005529174],"domain_scores_gemma":[0.9987362,0.0005573075,0.0001237863,0.0003572856,0.00004099362,0.0001843963],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7896433,0.02988525,0.07217538,0.002653144,0.0001106982,0.0009769175,0.03036403,0.0004523271,0.00196823,0.0006573992,0.00540211,0.06571124],"study_design_scores_gemma":[0.9763969,0.002803409,0.009499449,0.0002313902,0.0001339936,0.00000785988,0.0006664846,0.007910368,0.0008670107,0.0002033938,0.0005372028,0.0007425621],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9912792,0.002666455,0.00007608254,0.00007305555,0.0004811507,0.004468035,0.0001758972,0.00007866176,0.0007014843],"genre_scores_gemma":[0.9980515,0.00007792353,0.0001466137,0.0003083156,0.00003380562,0.0006958225,0.0000107115,0.0000679741,0.000607363],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1867536,"threshold_uncertainty_score":0.9999424,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04522785211261003,"score_gpt":0.3353546691208892,"score_spread":0.2901268170082791,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}